February 2026 in “Journal of the American Academy of Dermatology” Managing skin diseases during pregnancy and postpartum requires careful consideration of treatment safety and dosing to protect both mother and baby.
January 2026 in “Bioengineering” In this review, various expression systems for synthesizing recombinant collagen are compared, highlighting their efficiency, modification capabilities, and cost. Key purification techniques are also analyzed, and challenges like reducing R&D costs and improving safety protocols are identified.
January 2026 in “Journal of Radiation Research” This study found that using human hair follicle dermal papilla cells, 53BP1 focus counting can estimate radiation doses from 50 mGy after 5 hours, and focus size analysis refines dose estimation for doses ≥ 500 mGy up to 96 hours.
January 2026 in “Health Food & Biotechnology” This study developed a sustainable biotechnological process using Bacillus licheniformis strains to produce keratin hydrolysate from chicken feathers, and found that cosmetic hair serum with this ingredient improved hair smoothness, elasticity, and shine in a small focus group.
January 2026 in “National Journal of Pharmaceutical Sciences” This study developed and validated a Gas Chromatography-Flame Ionization Detection method for assessing minoxidil, which shows good precision, accuracy, and specificity for quality control and pharmacokinetic studies.
November 2025 in “Molecules” This review examines recent advancements in green and emerging microextraction techniques, such as SPME and DLLME, for more sustainable hormone detection in biological samples, emphasizing environmentally friendly solvents and bioanalytical applications.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
July 2025 in “International Journal of Trichology” This source discusses the ethical dilemmas and business pressures in cosmetic dermatology, emphasizing the shift toward commercialism and profit-driven practices influenced by social media and market demands, potentially leading to conflicts of interest and professional misconduct.
July 2025 in “Scientific Reports” In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.
This case study reports that early genetic testing and targeted therapies, such as secukinumab, can significantly improve skin barrier function in patients with Netherton syndrome, despite persistent symptoms.
April 2025 in “International Journal of Molecular Sciences” This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
January 2025 in “PLoS ONE” This study found that aligned electrospinning membranes enhance skin wound healing by upregulating MMP12 expression and inhibiting fibroblast migration, which results in reduced scar formation, providing valuable insights for developing more effective biological dressings.
Higher pre-pregnancy BMI is linked to more stress in mothers and more behavioral problems in two-year-old children.
January 2025 in “Stem Cells International” In this review, researchers discuss the role of epigenetic modifications in epidermal stem cells' decline during skin aging and identify potential interventions targeting these disruptions, suggesting significant possibilities for antiaging strategies and dermatological treatments.
November 2024 in “Revista fisio&terapia.” This literature review found that among therapies for Alopecia Areata, Janus kinase inhibitors are particularly promising despite safety challenges, while newer approaches like stem cells face cost and complexity issues; a comprehensive approach integrating medical and emotional support was emphasized for improving patient outcomes.
October 2024 in “Andrology” This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.
October 2024 in “Journal of Education Health and Sport” This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.
September 2024 in “Dokumentenrepositorium der RUB (Ruhr University Bochum)” This study found that patients with higher baseline monocyte counts (\(\geq\) 925/\(\mu\)l) were significantly more likely to see treatment failure with adalimumab for hidradenitis suppurativa.
September 2024 in “Journal of the American Academy of Dermatology” Organizations help patients access discounts for expensive dermatology medications.
August 2024 in “Polo del Conocimiento” This article discusses psoriasis, highlighting its common triggers, such as trauma and infections, and potential treatment options ranging from topical therapies to systemic medications like methotrexate for severe cases.
July 2024 in “Nursing Research” This study highlights the use of hair and fingernail cortisol levels as retrospective indicators of chronic stress, particularly in minoritized populations facing social stressors that increase the risk of mental health issues.
Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.
May 2024 in “Journal of Education, Health and Sport” This review article highlights the complexity of treating folliculitis decalvans, emphasizing the role of systemic antibiotics like rifampicin and clindamycin as common treatments, while also discussing promising novel therapies, including biological agents, that require further clinical trials to assess their effectiveness and safety.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
April 2024 in “Human genomics” This study identified MPB susceptibility genes and potential drug candidates that may help uncover molecular mechanisms and address male-pattern baldness.
February 2024 in “Current Drug Delivery” In this study, researchers developed an emulgel formulation containing minoxidil for hair growth, using chitosan and fucoidan as gelling agents, achieving controlled drug release with 99.7% released by the 12th hour.
February 2024 in “BIOspektrum” This review discusses the latest molecular genetic insights into male-pattern hair loss and their potential applications in improving prediction and treatment, without reporting new clinical results.
January 2024 in “Research Portal Denmark” This study reports the development of an artificial skin membrane incorporating hair follicles, intended as an in vitro model to better estimate drug permeation with less variability than current models used in transdermal drug delivery research.
January 2024 in “International Journal of Applied Research” In this cross-sectional study on Iraqis, 74.5% of participants self-reported hair loss following COVID-19 infection, with the highest prevalence among those aged 19-29, pointing to a potential link between COVID-19 and increased risk of telogen effluvium.
January 2024 in “Medical Research Archives” This source highlights the emerging field of psychodermatology, which examines the interplay between psychological factors and skin disorders, noting a historical lack of attention due to inadequate professional training and emphasizing the need for integrated care involving dermatologists, psychiatrists, and psychologists.